Shire's Vonvendi approved in surgical setting
A day after news broke that it was to sell its oncology business for $2.4 billion, Ireland-incorporated drugmaker Shire (LSE: SHP) has shown the strength of its hematology portfolio.
The company has announced that the US Food and Drug Administration (FDA) has expanded the use of its Vonvendi [von Willebrand factor (recombinant)] to include the perioperative management of bleeding in adutls with von Willebrand disease (VWD).
Vonvendi was first approved by the FDA for on-demand treatment and control of bleeding episodes in 2015. The product was developed by Baxalta and was acquired when Shire acquired the company in 2016. It is the first and only recombinant treatment for adults living with VWD, the most common inherited bleeding disorder. The condition affects up to 1% of the US population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze